Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: A Lupus Patient with Abdominal Pain

Emily Purcell, MD, Colin Ligon, MD, MHS, & Chris T. Derk, MD, MS  |  Issue: February 2021  |  February 16, 2021

SLE RelatedNon-SLE Related
Lupus enteritisAppendicitis
PancreatitisLithiasic cholecystitis
Pseudo-obstructionPeptic ulcer
Acalculous cholecystitisAcute pancreatitis
Mesenteric thrombosisRetroperitoneal hematoma
Hepatic thrombosisOvarian pathology
Medications (NSAIDs, MMF, steroids, HCQ …)Diverticulitis
Colon perforation (vasculitis)Adhesions, intestinal occlusion
Infectious enteritis
Pyelonephritis
CMV colitis
Key: NSAIDs: non-steroidal anti-inflammatory drugs; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine.

Table 2: Anatomic Distribution of GI Involvement among Patients with SLE2

OrganInvolvement
Mouth/pharynxOral ulcers
EsophagusDysphagia
Esophageal dysmotility
Gastric reflux
Bullous epidermolysis
Ulcerative esophagitis
StomachPeptic ulcer disease
Gastric enteritis
Dyspepsia
PancreasAcute pancreatitis
LiverHepatomegaly
Type 1 autoimmune hepatitis
Steatosis
Nodular regenerative hyperplasia
GallbladderPrimary sclerosing cholangitis
Autoimmune cholangiopathy
Acute acalculous cholangitis
Small IntestineCeliac disease
Mesenteric vasculitis
Protein-losing enteropathy
Cytomegalovirus enteritis
Intestinal pseudo-obstruction
ColonCrohn’s disease
Bowel perforation
Pneumatosis cystoides intestinalis
Benign pneumoperitoneum
Rectum, anusUlcerations
OtherAppendicitis
Primary lupus peritonitis
Splenomegaly
Ascites

Lupus Enteritis

According to the BILAG 2004 definition, lupus enteritis is either vasculitis or inflammation of the small bowel with supportive imaging and/or biopsy findings.4 It may also be called mesenteric arteritis, intestinal vasculitis, enteric vasculitis, mesenteric vasculitis, lupus peritonitis or abdominal serositis. 

Figure 4: Proposed Treatment Algorithm for SLE Patients with Lupus Enteritis3

Figure 4: Proposed Treatment Algorithm for SLE Patients with Lupus Enteritis3

Although the pathogenesis of lupus enteritis remains unknown, it has been reported that immune complex-mediated visceral vasculitis may result in bowel wall and mucosal edema.5 The most common clinical manifestations include abdominal pain, ascites, nausea, vomiting, diarrhea and fever (see Figure 3,).3

Lab findings in lupus enteritis include anemia (52%), leukocytopenia and/or lymphocytopenia (40%), thrombocytopenia (21%) and hypocomplementemia (88%).3 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A retrospective study by Koo et al. found C4 was significantly lower in patients with lupus enteritis.1 

A retrospective study and systematic literature review by Janssens et al. found the following lab abnormalities in patients with lupus enteritis: ANA (92%), anti-dsDNA (74%), anti-RNP (28%), anti-SSA (26%) and anti-Sm (24%) antibodies, proteinuria >0.5 g/24h (47%), positive antiphospholipid antibodies (30%). Seven patients in this study met criteria for antiphospholipid antibody syndrome.3 

In the same review, the authors found the most common radiographic findings were bowel wall edema (91%); double halo or target sign (71%); dilation of bowel lumen (24%); ascites (78%); mesenteric abnormal­ities (71%), including engorgement of mesenteric vessels; and increased number of viable vessels (comb sign).3 

Table 3  shows the frequency of CT findings in SLE patients with undiffer­entiated acute abdominal pain.6 The jejunum and ileum are more frequently involved, followed by the colon, duodenum and rectum. Of the cases identified in this review, 15% had endoscopy with normal macroscopic findings in 60%.3 Endoscopic biopsy is of low yield. Therefore, lupus enteritis is generally a diagnosis of exclusion. 

Table 3: CT Findings of SLE Patients with Undifferentiated Acute Abdominal Pain6

CT FindingsFrequency (%)
Engorgement of mesenteric vessels82
Ascites77
Bowel wall thickening74
Dilation of intestinal segments (5–13 mm)74
Comb sign (engorged mesenteric vessels)69
Target sign (bowel wall thickening and enhancement)66
Retroperitoneal lymphadenopathy61.5
Pleural effusion33
Splenomegaly33
Hepatomegaly25.6
Peritoneal enhancement23
Hydronephrosis23
Lupus nephritis23
Lupus cystitis15
Pancreatitis10
Venous thrombosis10
Splenic infarction5
Pneumatosis intestinalis2.5
Liver abscess2.5

Treatment

Corticosteroids are the initial treatment for all patients, with an average duration of four days (range 1–34 days).3 Cyclo­phosphamide can be considered, especially if there is other severe organ involvement (see Figure 4). Maintenance therapy typically includes hydroxychloroquine, mycophenolate mofetil or azathioprine.  Most patients have relief of symptoms in less than one week, and recurrence occurs in 23% of patients.3


Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:abdominal paincase reportgastrointestinallupus enteritis

Related Articles

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Mattew - Bilder und mehr / shutterstock.com

    Yao Syndrome: A Case Report & Clinical Review

    November 12, 2020

    Case Presentation History of present illness A 66-year-old white woman presented with unexplained, recurrent episodes of high fever, abdominal pain, rash and arthralgias occurring over the previous three years. During typical episodes, the patient experienced flu-like symptoms, followed by fever, abdominal pain and non-bloody diarrhea without tenesmus. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEHer temperatures were 101–103ºF,…

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences